why choose us

First received: November 15, 2022

Clinical Trial: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-Label Study of ABSK121-NX to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Brief Summary: This is an open-label phase 1 study with expansion.The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability.The expansion part will investigate oral ABSK121-NX at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types.Preliminary antitumor activity will also be assessed.

Read more